EIC Summit 25 Networking Platform

2–3 Apr 2025 | Brussels, Belgium

InvestmentUpdated on 27 March 2025

Invest in the Future of CRISPR Diagnostics

Niek Savelkoul

CEO at Scope Biosciences B.V.

Wageningen, Netherlands

About

Scope Biosciences has developed a modular CRISPR-Cas platform delivering rapid, SNP-specific diagnostics without the need for complex hardware. Already generating revenue in agriculture, we are now expanding into medical diagnostics with support from a 2.5M EIC Transition grant. We are progressing toward ISO13485 certification and clinical validation, with multiple product and partnership opportunities on the horizon. We’re seeking investors to join us at this critical growth phase

Stage

  • Growth and Establishment
  • Speed and Development
  • Startup

Applies to

  • Agriculture & Food
  • Health Biotechnology

Organisation

Scope Biosciences B.V.

Start-ups and SMEs

Wageningen, Netherlands

Similar opportunities

  • Partnership

    Partner with Scope Biosciences on CRISPR-based Diagnostic Co-Development

    • Development

    Niek Savelkoul

    CEO at Scope Biosciences B.V.

    Wageningen, Netherlands

  • Investment

    Series A

    • Energy
    • Expansion
    • AI, Data & ICT
    • Speed and Development
    • Growth and Establishment
    • Climate & Environmental Tech
    • Quantum, Advanced Computing & Semiconductors

    Lovisa Urheim

    Head of Strategic Initiatives at Plexigrid

    Stockholm, Sweden

  • Investment

    Serie A AURA AERO

    • Mobility
    • Speed and Development
    • Climate & Environmental Tech
    • Advanced Manufacturing & Advanced Materials

    Antoine Toulemont

    European Affairs Adviser at Aura Aero

    Brussels, Belgium